Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 30;19(1):56.
doi: 10.1186/s13223-023-00816-0.

A EUFOREA comment on a lost comorbidity of asthma

Diego M Conti  1 , Peter W Hellings  2   3   4   5 , Zuzana Diamant  2   6   7   8 , Leif Bjermer  6 , Milos Jesenak  9 , Vibeke Backer  10 , Wytske Fokkens  11 , Susanne Lau  12 , Elizabeth Van Staeyen  13 , Glenis K Scadding  14   15
Affiliations

A EUFOREA comment on a lost comorbidity of asthma

Diego M Conti et al. Allergy Asthma Clin Immunol. .

Abstract

"Epidemiology of comorbidities and their association with asthma control" (Tomisa, G., Horváth, A., Sánta, B. et al. Epidemiology of comorbidities and their association with asthma control. Allergy Asthma Clin Immunol 17, 95 (2021). https://doi.org/10.1186/s13223-021-00598-3 ) is an interesting paper reflecting data collection from more than 12,000 asthmatic patients in Hungary regarding their condition and associated comorbidities. We found it valuable that the paper provides an overview of asthma comorbidities not usually considered in similar reports. Nevertheless, we believe that chronic rhinosinusitis (CRS) with or without nasal polyps (CRSwNP or CRSsNP) should have been listed due to its high incidence and prevalence, its association with asthma which is also endorsed in both GINA and EPOS, as well as in several peer-reviewed scientific papers, and to reflect the role of this comorbidity in poor control and a most severe presentation of asthma for the patient. Consequently, several targeted therapies (especially monoclonal antibodies) used for several years in severe forms of asthma are now indicated also for the effective treatment of nasal polyps.

Keywords: Allergic rhinitis; Asthma; Chronic rhinosinusitis with nasal polyps; Chronic rhinosinusitis without nasal polyps; Comorbidities.

PubMed Disclaimer

Conflict of interest statement

Diego Conti is the academic manager at EUFOREA. He has no competing interest to declare. Peter Hellings is consultant and recipient of lecture fees and/or research grants from Sanofi, Regeneron, Novartis, GSK, ALK, and Viatris. Zuzana Diamant received in the past three years speaker fees or honoraria or serving on advisory boards or as a consultant from Antabio, Boehringer Ingelheim, Foresee Pharmaceuticals, GlaxoSmithKline, QPS-Netherlands, Sanofi-Genzyme-Regeneron, all outside the submitted work. Leif Bjermer has no competing interest to declare in relation to this work. Milos Jesenak reports receiving consultancy/speaker honoraria from CSL Behring, SOBI, Novartis, GSK, Sanofi, Viatris, and Takeda Pharmaceutical Co. Ltd.; and serving as a principal investigator for clinical trials sponsored by Takeda, Mundipharma, Octapharma, BioCryst Pharmaceuticals, Inc. and Pharming Group NV. Vibeke Backer has no competing interest to declare in relation to this work. Wytske Fokkens has no competing interest to declare in relation to this work. Susanne Lau has received honoraria for lectures and AD Boards from Sanofi-Aventis, DBV, Allergopharma, ALK, Leti, GSK, and Leo Pharma in the last three years. Elizabeth Van Staeyen is the Scientific Communications & Advocacy Manager at EUFOREA. She has no competing interest to declare. Glenis Scadding is a Board member of EUFOREA. She has received remuneration from Sanofi Regeneron and has undertaken trials for GSK.

References

    1. Tomisa G, Horváth A, Sánta B, et al. Epidemiology of comorbidities and their association with asthma control. Allergy Asthma Clin Immunol. 2021;17:95. doi: 10.1186/s13223-021-00598-3. - DOI - PMC - PubMed
    1. Sedaghat AR, Kuan EC, Scadding GK. Epidemiology of Chronic Rhinosinusitis: prevalence and risk factors. J Allergy Clin Immunol Pract. 2022;10(6):1395–403. doi: 10.1016/j.jaip.2022.01.016. - DOI - PubMed
    1. Jarvis D, Newson R, Lotvall J, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67:91–8. doi: 10.1111/j.1398-9995.2011.02709.x. - DOI - PubMed
    1. Fokkens WJ, Lund VJ, Hopkins C et al. Executive summary of EPOS 2020 including integrated care pathways. Rhinology. 2020 Apr 1;58(2):82–111. 10.4193/Rhin20.601. PMID: 32226949. - PubMed
    1. De Prins L, Raap U, Mueller T, Schmid-Grendelmeier P, Haase CH, Backer V, Fokkens W, Benoist LB, Prokopakis E, Hopkins C, Claeys N, Teeling T, Cypers L, Cools L, Bjermer LH, Diamant Z, Wahn U, Scadding G, Bachert C, Patel SR, Van Staeyen E, Hellings P. White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA. Front Allergy. 2022 Jun 2;3:889221. 10.3389/falgy.2022.889221. Erratum in: Front Allergy. 2022 Sep 09;3:1001078. PMID: 35769567; PMCID: PMC9234878. - PMC - PubMed

LinkOut - more resources